Table 2. aGVHD and cGVHD Item and... | American Society of Hematology

Table 2.

aGVHD and cGVHD

Item and specification	n	aGVHD °II-IV			aGVHD °III-IV				cGVHD
Item and specification	n	Prob.	95% CI	P	Prob.	95% CI	P	n	Prob.	95% CI	P
Number of patients at risk	70	24	16-37		7	3-17		68	11	5-22
Year of HSCT
<2000	19	26	12-56		11	3-39		18	22	9-53
≥2000	51	24	14-39	NS	6	2-18	NS	50	7	2-20	.04
Sex
Male	44	23	13-39		9	4-23		44	14	7-29
Female	26	27	14-51	NS	4	1-26	NS	24	4	1-28	NS
Age at HSCT, y
<10	52	21	13-36		4	1-15		51	8	3-21
10-18	18	33	17-64	NS	17	6-47	.07	17	18	6-49	NS
<5	34	18	9-36		3	0-20		34	9	3-27
5-9	18	28	13-59		6	1-37		17	6	1-42
10-14	13	15	4-55		0			12	17	5-59
15-18	5	80	52-100	.01	60	29-100	<.01	5	20	3-100	NS
Number of transfusions (n = 54)
<20	10	10	2-64		0			10	0
20-50	22	23	11-49		9	2-34		22	9	2-34
>50	22	32	17-59	NS	9	2-34	NS	21	10	3-37	NS
Ferritin prior to HSCT (n = 51)								12	9	1-59
<1000	12	8	1-54		0
≥1000	39	28	17-47	NS	10	4-26	NS	38	6	2-22	NS
Donor
MSD	45	18	9-33	.10	4	1-25		44	12	5-27
UD	25	36	21-61		8	2-30	NS	24	9	2-33	NS
Donor, HSCT ≥2000
MSD	27	11	4-32		11	3-41		27	8	2-29
UD	24	38	22-63	.04	8	2-31	NS	23	5	1-32	NS
Stem cell source
BM	56	25	16-39		7	3-18		56	11	5-24
PBSCs	7	42	18-100		14	2-88		5	0
CB (sibling)	7	0		NS	0		NS	7	14	2-88	NS
Conditioning regimen
Bu/Cy	35	14	6-32		3	0-20		33	9	3-27
Bu other	13	23	9-62		0			13	9	1-59
Treo/TT/Flu	13	46	26-83		15	4-55		13	0
Other	9	33	13-84	NS	22	7-75	.08	9	33	13-84	.06
ATG/ALG
Yes	57	26	17-41		7	3-18		56	5	2-16
No	13	15	4-55	NS	8	1-51	NS	12	33	15-74	<.01

Item and specification	n	aGVHD °II-IV			aGVHD °III-IV				cGVHD
Item and specification	n	Prob.	95% CI	P	Prob.	95% CI	P	n	Prob.	95% CI	P
Number of patients at risk	70	24	16-37		7	3-17		68	11	5-22
Year of HSCT
<2000	19	26	12-56		11	3-39		18	22	9-53
≥2000	51	24	14-39	NS	6	2-18	NS	50	7	2-20	.04
Sex
Male	44	23	13-39		9	4-23		44	14	7-29
Female	26	27	14-51	NS	4	1-26	NS	24	4	1-28	NS
Age at HSCT, y
<10	52	21	13-36		4	1-15		51	8	3-21
10-18	18	33	17-64	NS	17	6-47	.07	17	18	6-49	NS
<5	34	18	9-36		3	0-20		34	9	3-27
5-9	18	28	13-59		6	1-37		17	6	1-42
10-14	13	15	4-55		0			12	17	5-59
15-18	5	80	52-100	.01	60	29-100	<.01	5	20	3-100	NS
Number of transfusions (n = 54)
<20	10	10	2-64		0			10	0
20-50	22	23	11-49		9	2-34		22	9	2-34
>50	22	32	17-59	NS	9	2-34	NS	21	10	3-37	NS
Ferritin prior to HSCT (n = 51)								12	9	1-59
<1000	12	8	1-54		0
≥1000	39	28	17-47	NS	10	4-26	NS	38	6	2-22	NS
Donor
MSD	45	18	9-33	.10	4	1-25		44	12	5-27
UD	25	36	21-61		8	2-30	NS	24	9	2-33	NS
Donor, HSCT ≥2000
MSD	27	11	4-32		11	3-41		27	8	2-29
UD	24	38	22-63	.04	8	2-31	NS	23	5	1-32	NS
Stem cell source
BM	56	25	16-39		7	3-18		56	11	5-24
PBSCs	7	42	18-100		14	2-88		5	0
CB (sibling)	7	0		NS	0		NS	7	14	2-88	NS
Conditioning regimen
Bu/Cy	35	14	6-32		3	0-20		33	9	3-27
Bu other	13	23	9-62		0			13	9	1-59
Treo/TT/Flu	13	46	26-83		15	4-55		13	0
Other	9	33	13-84	NS	22	7-75	.08	9	33	13-84	.06
ATG/ALG
Yes	57	26	17-41		7	3-18		56	5	2-16
No	13	15	4-55	NS	8	1-51	NS	12	33	15-74	<.01

NS, nonsignificant; Prob., probability; TT, thiotepa.